PolyPid (PolyPid) EV-to-EBITDA : -1.32 (As of Apr. 30, 2024)

View and export this data going back to 2020. Start your Free Trial

What is PolyPid EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PolyPid's enterprise value is $29.27 Mil. PolyPid's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.18 Mil. Therefore, PolyPid's EV-to-EBITDA for today is -1.32.

The historical rank and industry rank for PolyPid's EV-to-EBITDA or its related term are showing as below:

PYPD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.97 Med: 0 Max: 0.1
Current: -1.32

During the past 10 years, the highest EV-to-EBITDA of PolyPid was 0.10. The lowest was -2.97. And the median was 0.00.

PYPD's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.09 vs PYPD: -1.32

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), PolyPid's stock price is $4.7721. PolyPid's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-19.670. Therefore, PolyPid's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

PolyPid EV-to-EBITDA Historical Data

The historical data trend for PolyPid's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid EV-to-EBITDA Chart

PolyPid Annual Data

Trend

Dec12

Dec13

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-3.87

-1.82

-0.41

-0.63

PolyPid Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-0.41	-0.53	-0.57	-0.40	-0.63

Competitive Comparison of PolyPid's EV-to-EBITDA

For the Biotechnology subindustry, PolyPid's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PolyPid's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PolyPid's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PolyPid's EV-to-EBITDA falls into.

PolyPid EV-to-EBITDA Calculation

PolyPid's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	29.269	/	-22.178
	=	-1.32

PolyPid's current Enterprise Value is $29.27 Mil.
PolyPid's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.18 Mil.

PolyPid (NAS:PYPD) EV-to-EBITDA Explanation

PolyPid's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	4.7721	/	-19.670
	=	At Loss

PolyPid's share price for today is $4.7721.
PolyPid's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.670.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

PolyPid EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PolyPid's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

PolyPid (PolyPid) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376

Website

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, and Bacyssio are trademarks of the company. The company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.